HIV-1-Infected Antiretroviral-Treated Patients With Prolonged Partial Viral Suppression: Clinical, Virologic, and Immunologic Course.
Tenorio, Allan R. MD; Smith, Kimberly Y. MD, MPh; Kuritzkes, Daniel R. MD; Sha, Beverly E. MD; Donoval, Betty; Young, Russell; Jennings, Cheryl; Bremer, James PhD; Shott, Susan PhD; Landay, Alan PhD; Kessler, Harold A. MD
[Report] JAIDS Journal of Acquired Immune Deficiency Syndromes. 34(5):491-496, December 15, 2003.

(Format: HTML, PDF)

Summary: The long-term feasibility of a drug conservation strategy that allows low-level viral replication is unknown. We performed a retrospective study of treated HIV-infected patients with stable detectable viral replication (<10,000 copies/mL [low-level viremia]) and compared their clinical, virologic and immunologic courses with those of treated patients with undetectable viremia and viremia (>=10,000 copies/mL [high-level viremia]). Viral reverse transcriptase and protease genotype and HIV-specific CD4 T-cell responses were determined using patient-derived samples. Clinical and immunologic benefits were maintained in patients with partial virologic suppression (<=10,000 copies/mL). Although low-level viral replication under drug pressure led to the accumulation of resistance mutations in most subjects' viruses, most subjects retained susceptibility to drugs in >=2 classes of antiretroviral medications. HIV-specific CD4 T-cell immunity was detected in most subjects with low-level and undetectable viremia and may have a role in controlling viremia in the setting of partial suppression.

Copyright (C) 2003 Wolters Kluwer Health, Inc. All rights reserved.